Mean platelet volume-to-lymphocyte ratio: a novel biomarker associated with overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy

Abstract

Introduction Renal cell carcinoma is a highly aggressive malignancy that causes significant morbidity and mortality. The rising number of newly diagnosed renal tumors results in a great need to search for new preoperative markers to evaluate the course of the disease and to help select patients who would benefit the most from additional postoperative care. The aim of our study was to evaluate the prognostic value of mean platelet volume-to-lymphocyte ratio (MPVLR) in patients undergoing nephrectomy for nonmetastatic clear cell renal cell carcinoma (ccRCC). Materials and methods A total number of 344 patients with proven nonmetastatic ccRCC treated with radical or partial nephrectomy at our institution between January 2003 and December 2012 were included in our analysis. Based on the optimal cutoff value of MPVLR, which was determined by the receiver operating characteristic curve, our study population was divided into two groups, with low and high MPVLR. Differences in overall survival between groups were compared using the Kaplan-Meier method with log-rank testing. The Cox proportional hazards regression model was applied to perform univariate and multivariate analysis. Results Study subjects with high MPVLR were older and had more advanced tumors. Tumor necrosis and higher TNM stages were also more prevalent in this group of patients. Mortality in patients with high MPVLR was significantly higher than in patients with low MPVLR. In the multivariate analysis, after adjustment for pathological and clinical covariates, high MPVLR (≥ 3.61) was independently associated with higher long-term overall mortality in nonmetastatic ccRCC patients. Conclusion MPVLR is an easily obtainable prognostic marker for overall survival in nonmetastatic ccRCC patients treated with nephrectomy.

The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia

“…So far MPVLR has been widely studied in cardiovascular disease, and inflammatory response, but few in tumor prognosis. A recent study proved that high MPVLR (≥3.61) was independently associated with higher long-term overall mortality in nonmetastatic ccRCC patients ( 34 ). Our study was the first to investigate whether MPVLR was associated with the recurrence of patients with NMIBC.…”

Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies

“… Życzkowski M et al, 64 Invasive breast cancer (IBC) High pre-treatment MPV level in IBC patients was a potential predictive factor. Gu M et al, 65 BC The combination of preoperative D-Dimer and MPV improves the predictive power of postoperative deep venous thrombosis risk in BC patients. Cui LN et al, 66 Breast cancer with bone metastases MPV can be used to predict the development of isolated bone metastases patients with breast cancer.…”

“…Życzkowski M et al, 64 Invasive breast cancer (IBC) High pre-treatment MPV level in IBC patients was a potential predictive factor. Gu M et al, 65…”

Comment on “Mean platelet volume-to-lymphocyte ratio: a novel biomarker associated with overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy”

“…We read the research study conducted by Zyczkowski et al [1] related with "Mean platelet volume-to-lymphocyte ratio: a novel biomarker associated with overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy" which was published in your journal, with great interest. This study's findings indicated that mean platelet volume-to-lymphocyte ratio (MPVLR) is an easily obtainable prognostic marker for overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy.…”